Fetuin-Mineral Complex Reflects Extraosseous Calcification Stress in CKD

Takayuki Hamano,* Isao Matsui,* Satoshi Mikami,† Kodo Tomida,‡ Naohiko Fujii,§ Enyu Imai,* Hiromi Rakugi,* and Yoshitaka Isaka*

*Department of Geriatric Medicine and Nephrology, Osaka University Graduate School of Medicine, Osaka, Japan; †Department of Internal Medicine, Higashikohri Hospital, Osaka, Japan; ‡Department of Internal Medicine, Kansai-Rosai Hospital, Hyogo, Japan; and §Department of Internal Medicine, Hyogo Prefectural Nishinomiya Hospital, Hyogo, Japan

ABSTRACT

Fetuin-A is an important inhibitor of extraosseous calcification, but some of the studies that used ELISAs did not identify a significant relationship between serum fetuin-A levels and vascular calcification in patients with chronic kidney disease (CKD). Here, we used centrifugation to separate a fetuin-mineral complex (FMC) composed of fetuin-A, fibrinogen, fibronectin-1, and calcium from the serum of hemodialysis patients. In addition, we analyzed serum fetuin-A levels of 73 patients with diabetes and CKD (predialysis) after centrifugation. Fetuin-A concentrations were significantly lower in supernatants than in serum from patients at any stage of CKD, indicating systemic circulation of FMC in these patients. With greater severity of CKD, the contribution of FMC to total fetuin-A increased. Despite the absence of a correlation between serum fetuin-A and coronary artery calcification scores (CACS), supernatant fetuin-A negatively correlated with CACS and the extent to which centrifugation reduced fetuin-A (reduction ratio [RR]) positively correlated with CACS. In a longitudinal study of 12 hemodialysis patients with secondary hyperparathyroidism, parathyroidectomy and cinacalcet therapy each significantly reduced the RR without changing supernatant fetuin-A levels after 1 month, suggesting a reduction in FMC. Moreover, the magnitude of cinacalcet-induced reduction in parathyroid hormone correlated with the decrease in RR but not with changes in serum or supernatant fetuin-A. These data suggest that a quantitative measure of FMC, not supernatant or serum fetuin-A as measured in previous studies, reflects extraosseous calcification stress.


Medial vascular calcification is a frequent complication of aging, diabetes, and chronic kidney disease (CKD).¹⁻³ It causes blood vessels to stiffen, which leads to increased systolic BP, reduced diastolic BP, increased pulse pressure, and a resultant higher risk for cardiovascular mortality, thus highlighting the importance of accurately evaluating risk status for vascular calcification.⁶⁻⁷

Many promoters and inhibitors participate in the complex pathogenesis of vascular calcification. Among several putative calcification inhibitors, the reverse acute-phase protein fetuin-A is a good candidate extraosseous calcification inhibitor, particularly in patients with CKD.⁸⁻⁹ Abundant serum glycoprotein fetuin-A (also called α-2 Heremans Schmid glycoprotein) is synthesized in the liver and secreted into the bloodstream, from which it po-

Received September 16, 2009. Accepted May 24, 2010.
PUBLISHED ONLINE AHEAD OF PRINT Publication date available at www.jasn.org.
T.H. and I.M. contributed equally to this work.

Correspondence: Dr. Takayuki Hamano, Department of Geriatric Medicine and Nephrology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan. Phone: +81-6-6879-3857; Fax: +81-6-6879-3857; E-mail: hamatea@medone.med.osaka-u.ac.jp
Copyright © 2010 by the American Society of Nephrology

Received September 16, 2009. Accepted May 24, 2010.
PUBLISHED ONLINE AHEAD OF PRINT Publication date available at www.jasn.org.
T.H. and I.M. contributed equally to this work.

Correspondence: Dr. Takayuki Hamano, Department of Geriatric Medicine and Nephrology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan. Phone: +81-6-6879-3857; Fax: +81-6-6879-3857; E-mail: hamatea@medone.med.osaka-u.ac.jp
Copyright © 2010 by the American Society of Nephrology

1998 ISSN : 1046-6673/2111-1998

tently inhibits ectopic calcification. Ketteler et al. demonstrated a relationship between all-cause/cardiovascular mortality and low serum fetuin-A levels in patients who were on hemodialysis (HD); since then, fetuin-A has received considerable focus. A significant correlation between low serum fetuin-A and vascular calcification has been verified by several other investigators.

Despite such accumulating evidence, we could not identify a significant relationship between serum fetuin-A and coronary artery calcification scores (CACS) in predialysis patients with CKD. In addition to our findings, Mehrotra et al., Jung et al., Hermans et al., and Ix et al. also reported that low serum fetuin-A is not an independent predictor of vascular calcification in patients with CKD. To determine why serum fetuin-A levels did not correlate with CACS in our previous clinical study, we studied rats that had adenine-induced renal failure (AIRF) and exhibited medial vascular calcification with reduced levels of serum fetuin-A. Intermittent weekly injection of alendronate eliminated vascular calcification but did not change serum fetuin-A levels, thus showing that these values do not always reflect the extent of vascular calcification; however, the centrifugation of serum from rats with AIRF yielded a small pellet comprising a complex of fetuin-A and calcium (FMC) that was undetectable in serum from normal rats and those that were administered injections of alendronate. Analysis in vitro revealed that the amount of FMC reflects a risk for mineral precipitation. On the basis of these findings, we speculated that a similar phenomenon exists in patients with CKD and explains why a significant relationship between serum fetuin-A levels and CACS could not be identified. Here, we examined whether the serum of patients with CKD actually contains FMC and explored a novel method of analyzing fetuin-A that is helpful for evaluating extraosseous calcification stress.

RESULTS

Serum from Patients Who Were on HD Contained FMC

Our previous study of rats with AIRF found that the serum of these rats contained FMC, which could be separated by centrifugation at 16,000 × g. The FMC closely correlated with extraosseous calcification stress and was never detected in normal control rats. To determine whether FMC could be similarly separated from patients on dialysis, we compared FMC levels in the serum from normal control subjects and patients who were on maintenance HD. Serum samples that were separated by centrifugation for 15 minutes at room temperature at 3000 × g were centrifuged once again for 2 hours at 16,000 × g at 4°C (Figure 1) to generate a small pellet. Proteins in the pellet were analyzed by Coomassie Brilliant Blue–stained polyacrylamide gel (Figure 2A). The pellets from the patients’ serum contained proteins of 250, 78, 68, 53, 50, 40, 26, and 25 kD (Figure 2A). We conducted matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF/MS) and identified the proteins as fibronectin-1, μ heavy chain, albumin, fibrinogen, fetuin-A, β-actin, Ig κ chain, and apolipoprotein A-I, respectively (Figure 2A, Supplemental Table 1). In the supernatant of the serum or supernatant fetuin-A are measured using ELISA. Supernatants are discarded, then centrifuge tubes are rinsed twice with 150 mM NaCl and re-centrifuged. Resultant pellets are dissolved in 150 mM HCl for calcium analysis. Pellets are dissolved in Laemmli buffer containing 60 mM EDTA and resolved by Super-Sep PAGE. Proteins of interest are identified by Coomassie Brilliant Blue (CBB) staining and MALDI-TOF/MS.

Levels of Fetuin-A are Lower in Supernatant than in Serum at All CKD Stages

To determine whether the reduction in fetuin-A caused by centrifugation at 16,000 × g is limited to patients who are on HD, we measured fetuin-A levels in the serum and supernatant of predialysis patients who had diabetes and CKD, who presumably have vascular calcification. Fetuin-A levels were comparable in the supernatant and serum of normal individuals (Figure 3Aa) but significantly lower in the supernatant than in serum at all CKD stages (Figure 3A, b through e). We calculated the fetuin-A reduction ratio (RR) by centrifugation to assess the ratio of sedimented fetuin-A (i.e., FMC in total serum fetuin-A; Figure 3B). The Jonckheere-Terpstra test confirmed a stepwise increase in RR with the progression of CKD (P < 0.05 for trend; Figure 3B).
values were lower with this ELISA kit, the serum fetuin-A levels (Figure 4A, vertical axis) closely correlated with those measured using the Epitope Diagnostic ELISA (Figure 4A, horizontal axis). The fetuin-A reduction in the supernatant was similar with both the Epitope Diagnostic (Figure 4B) and BioVendor (Figure 4C) fetuin-A ELISA kits. The RRs derived from the two kits also closely correlated (Figure 4D). All of these data indicate that the fetuin-A reduction after 16,000 x g centrifugation was not specific to either of the ELISA kits. Fetuin-A in the supernatant fraction was indeed reduced after centrifugation at 16,000 x g, and the reduction was not limited to a specific CKD stage. Patients with diabetes at any stage of CKD had FMC.

**Fetuin-A RR but not Serum Fetuin-A Level Correlated with Extraosseous Calcification Stress**

Although many investigators have found that serum fetuin-A levels negatively correlate with extraosseous calcification,\(^1,10,12–14\) we did not identify any significant relationship between serum fetuin-A concentrations and CACS in predialysis patients with diabetes and CKD.\(^15\) To further our previous clinical findings, we investigated relationships between CACS and serum fetuin-A, supernatant fetuin-A, or RR. Plots in Figure 5 show CACS versus serum fetuin-A, supernatant fetuin-A, or RR. In agreement with our previous findings,\(^15\) a significant correlation between CACS and serum fetuin-A (Figure 5A) was not found; however, significant relationships emerged between CACS and fetuin-A after fractionation into supernatant and sediment. Supernatant fetuin-A negatively and RR positively correlated with CACS (Figure 5, B and C, respectively). Moreover, the RR of fetuin-A was significantly associated with serum osteoprotegerin (\(r = 0.25, P < 0.05\)), which is an independent determinant of CACS in this population (data not shown).\(^15\)

We further analyzed whether potential therapeutic interventions for extraosseous calcification stress alters the fetuin-A fractions. Because secondary hyperparathyroidism is an established extraosseous calcification stressor in patients with CKD and because parathyroidectomy (PTX) often regresses ectopic calcification,\(^21–24\) we investigated the effects of PTX on fetuin-A fractions in HD patients. The effects of cinacalcet (25 mg/d) administration, a potential therapeutic intervention for extraosseous calcification stress,\(^25–27\) were also investigated. Twelve patients who were on HD underwent PTX (\(n = 4\)) or were administered cinacalcet (\(n = 8\)), and then serum samples from the two groups were analyzed 1 month later. We confirmed in two of the patients who underwent PTX that CACS decreased 6 months later by the intervention (before 8006 → after 7168, and before 5204 → after 3980). Supernatant fetuin-A levels persisted at essentially the same levels in all patients (Figure 6Aa), whereas serum fetuin-A (data not shown) and RR (Figure 6Ab) were significantly reduced, indicating that the ratio of FMC to total serum fetuin-A was also significantly reduced. We further examined relationships among changes in RR, serum fetuin-A, intact parathyroid hormone (iPTH), serum adjusted calcium, and phosphate and its product in patients who were treated with

---

To exclude the possibility that the results shown in Figures 2 and 3 were caused by artifacts that are unique to the Epitope Diagnostic ELISA kits, we analyzed serum and supernatant samples from 13 patients with stage 4 CKD using another fetuin-A ELISA kit purchased from BioVendor (Figure 4). Although the absolute

---
cinacalcet, in whom none of calcium-based phosphate binders or vitamin D or its analog concomitantly changed. Cinacalcet reduced iPTH from 441.9 ± 226.1 to 249.4 ± 118.7 pg/ml and calcium phosphate product from 47.2 ± 8.1 to 39.1 ± 8.1 mg²/dl². 

The reductions in iPTH and in serum fetuin-A levels did not correlate (Figure 6B); only the change in the RR of fetuin-A positively correlated with the reduction in iPTH (Figure 6C). These findings suggested that the RR of fetuin-A—that is, the ratio (%) of FMC to total fetuin-A but not serum or supernatant fetuin-A—accurately reflects extraosseous calcification stress.

**DISCUSSION**

We examined the behavior of fetuin-A in patients with CKD and found that the characteristics of fetuin-A also change under extraosseous calcification stress in humans. The following findings support this conclusion: The serum of patients who were on HD contained FMC, which was undetectable in normal serum; the 16,000 g supernatant that was obtained from serum contained less fetuin-A than serum in patients with diabetes and CKD; the RR of fetuin-A (the ratio of FMC to total fetuin-A) increased with CKD progression; supernatant fetuin-A negatively and RR positively correlated with CACS; and the decrease in iPTH induced by cinacalcet was significantly associated with the decrease in RR but not with that of serum or supernatant fetuin-A. These data suggest that more extraosseous calcification stress in patients with CKD is reflected in a higher ratio of fetuin-A sedimentation. Our results also suggest that previous clinical findings of fetuin-A should be interpreted with care because sample preparation, including blood centrifugation speed, affects the results.

Although Heiss et al. described dialysis-associated calcifying peritonitis with calciprotein particle (a synonym for FMC) in ascites, whether FMC really exists in human serum has remained obscure. Here, we discovered that serum from patients who are on HD contains FMC (Figure 2).

**Figure 3.** The ratio of FMC contained in the serum of predialysis patients increases with greater severity of CKD. Fetuin-A levels measured by ELISA (Epitope Diagnostic) are significantly reduced at all stages of CKD after centrifugation at 16,000 × g. Serum is processed as described in Figure 1. (A) Serum and supernatant fetuin-A levels are comparable in normal individuals (a), whereas supernatant levels are significantly lower than those of serum in patients with stages 1 and 2 CKD (b). Results are similar for stages 3 (c), 4 (d), and 5 CKD (e). Normal control subjects, n = 11; stages 1 and 2 CKD, n = 15; stage 3 CKD, n = 28; stage 4 CKD, n = 15; stage 5 CKD, n = 15 (Wilcoxon signed-ranks test). (B) RR of fetuin-A increases with CKD progression (P < 0.05 for trend; Jonckheere-Terpstra test). *Stage 5 serves as reference for Dunnet test.

**Figure 4.** Comparison of fetuin-A ELISA kits from two manufacturers. (A) Serum fetuin-A concentrations measured using BioVendor (vertical axis) and Epitope Diagnostic (horizontal axis) ELISA kits closely correlate (r = 0.664, P < 0.05). (B and C) Fetuin-A levels measured using Epitope Diagnostic (B) and BioVendor (C) ELISA kits reveal similar fetuin-A reductions in supernatant from serum of patients (n = 13) with stage 4 CKD (n = 13; P < 0.001, Wilcoxon signed-ranks test). (D) RR also closely correlates between kits (n = 13; r = 0.689, P < 0.01).
that contained little fetuin-A but large amounts of albumin.\textsuperscript{28} FMC in the serum contained at least three proteins: Fetuin-A, fibrinogen, and fibronectin-1. We and others have demonstrated that rat serum contains FMC under several experimental conditions.\textsuperscript{20,29–31} The FMC in human serum was also different from that in rat serum because FMC in rats with AIRF did not contain fibrinogen and fibronectin-1.\textsuperscript{20} In addition, matrix Gla protein and secreted phosphoprotein 24 (spp24), components of FMC in etidronate-treated rats, could not be identified in human serum FMC.\textsuperscript{31,32} Like lipoprotein particles, there may be several types of FMC under different conditions. Further studies are required to address this question. In addition to serum proteins, we detected β-actin in the pellet fraction both in normal control subject and HD patients (Figure 2A). Because of the low centrifugation speed in the first serum separation step, it seems that several cellular components, such as platelets and/or their microparticles, were sedimented with FMC in the second centrifugation step at 16,000 × g.

The sedimentation of fetuin-A by centrifugation at 16,000 × g was not restricted to the patients who were on HD. Fetuin-A similarly sedimented in serum samples from patients with diabetes at all stages of CKD but not in that from normal individuals (Figure 3A). Moreover, RR increased with the progression of CKD (Figure 3B). A possible mechanism for these observations on the basis of our findings in animals is schematically summarized in Figure 7.\textsuperscript{20} Fetuin-A exists in normal serum in the free form; that is, not bound to minerals (Figure 7A, top). Like other serum proteins, free fetuin-A does not sediment at 16,000 × g; therefore, the concentration of fetuin-A in the supernatant (Figure 7A, bottom) is equal to that in serum (Figure 7A, top). In contrast, fetuin-A forms FMC, which could be separated at 16,000 × g, to inhibit mineral precipitation under extraosseous calcification stress (Figure 7B). Under this condition, serum contains both free fetuin-A and fetuin-A as FMC (Figure 7B). Consequently, the amount of fetuin-A in the supernatant (Figure 7B, bottom) becomes lower than that in serum (Figure 7B, top). The difference between serum and supernatant fetuin-A values reflects the amount of fetuin-A as FMC (Figure 7B, bottom, pellet). In addition to these HD patients, patients with CKD at all stages had FMC (Figure 3).

We quantified the ratio of fetuin-A bound as FMC to total fetuin-A using RR, which was calculated using the formula shown in Figure 3B. Although not significantly associated with serum fetuin-A in predialysis patients with CKD (Figure 5A), CACS was positively related to RR (Figure 5C). Moreover, RR positively correlated with serum osteoprotegerin, which is associated with silent coronary artery disease in patients with type 2 diabetes.\textsuperscript{33} Levels of supernatant fetuin-A negatively correlated in parallel with CACS (Figure 5B). Furthermore, the reduction in iPTH induced by cinacalcet correlated with changes in RR but not with reduced serum or supernatant fetuin-A levels in HD patients with secondary hyperparathyroidism (Figure 6). Consistent with our results from animal experiments,\textsuperscript{20} these two findings (Figures 5 and 6) show that RR may be a reliable indicator of extraosseous calcification stress. Truly, the correlation of supernatant fetuin-A with CACS seems to be stronger than that with RR (Figure 5). Although there was no significant correlation between RR and serum albumin, we observed a significant positive correlation between supernatant fetuin-A and serum albumin ($R = 0.09, P = 0.001$). Given that malnutrition is a factor contributing to vascular calcification, it is reasonable that we found a stronger correlation of supernatant fetuin-A with CACS\textsuperscript{34}; however, supernatant fetuin-A levels seem less reliable markers because intervention for secondary hyperparathyroidism did not alter supernatant fetuin-A levels (Figure 6A). These fetuin-A fractions should be considered so that the risk for extraosseous calcification can be evaluated.

Fetuin-A is reported to be associated with intimal calcification as well as medial calcification.\textsuperscript{34} In fact, it was found in an animal study that overriding a fetuin-A deficiency in apolipoprotein-E–deficient mice that had CKD and were fed a high-phosphate diet promotes the intimal calcification of athromatous lesions.\textsuperscript{34} We postulated that the patients with diabetes and CKD in this study had intimal in addition to medial calcification.
The findings of our previous animal experiments showed that the appearance of serum FMC preceded the onset of vascular calcification. Given that FMC prevented the spontaneous precipitation of minerals \textit{in vitro}, the appearance of FMC seems to represent compensation for ongoing calcification stress in CKD; hence, the amount of FMC might serve as a marker of ongoing calcification stress. In this context, early changes in FMC (reflected in RR) by any intervention may predict the progression of ectopic calcification. In fact, in two PTX cases in which we followed CACS 6 months after the interventions, the decrease in RR preceded the decrease in CACS. Future studies are required to confirm the significance of RR as a predictor in clinical practice.

In this study, we did not elucidate the origin of FMC. Because ectopic artery calcification is often accompanied by decreased bone mineral density or disturbed bone turnover, FMC might be generated in the bone. Indeed, Price et al. reported that exceedingly large, nontherapeutic doses of etidronate generate FMC in rat by inhibiting normal bone mineralization. Because PTX or cinacalcet administration was as-
associated with the decrease in RR in this study, it seems possible that the change in bone health is an important factor for the appearance of FMC in humans, too; however, because we did not directly assess the bone health in these cases, there still remains several other possible origins of FMC, such as calcium and phosphate absorber (i.e., intestine). Future studies are required to clarify the origin of FMC in patients with CKD. This would help us to understand the role of FMC in relation to extraosseous calcification stress.

Our results suggested that the results of previous clinical studies should be carefully interpreted because either ELISA or nephelometry has been used to measure fetuin-A (Table 1). We summarized published clinical studies of the relationship between fetuin-A and extraosseous calcification and/or mortality (Table 1). In a previous study, we used an ELISA to analyze fetuin-A levels in clinical serum samples separated by centrifugation at \(3000 \times g\). Although most studies that used fetuin-A ELISA kits did not describe details of sample preparation, serum samples are usually separated at low-speed centrifugation in clinical situations. Thus, the serum fetuin-A determined by ELISA in previous clinical studies corresponds to the serum fetuin-A in this study; that is, the sum of free fetuin-A and fetuin-A in FMC. Several other studies used nephelometry, which determines levels of target molecules on the basis of turbidity.

Table 1. Clinical studies on the relationship between fetuin-A and extraosseous calcification and/or mortality

<table>
<thead>
<tr>
<th>Reference</th>
<th>Subjects</th>
<th>Centrifugation</th>
<th>Analytic Methods</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ketteler et al. (2003)(^{11})</td>
<td>HD patients</td>
<td>ND</td>
<td>Original indirect ELISA</td>
<td>Serum fetuin-A deficiency enhances mortality.</td>
</tr>
<tr>
<td>Mehrotra et al. (2005)(^{16})</td>
<td>Patients with type 2 diabetes</td>
<td>ND</td>
<td>Original indirect ELISA</td>
<td>Serum fetuin-A positively correlates with CACS.</td>
</tr>
<tr>
<td>Moe et al. (2005)(^{1})</td>
<td>Patients with stage 5 CKD</td>
<td>ND</td>
<td>Nephelometry</td>
<td>Low serum fetuin-A correlates with increased CACS.</td>
</tr>
<tr>
<td>Stenvinkel et al. (2005)(^{12})</td>
<td>Patients with stage 5 CKD</td>
<td>ND</td>
<td>ELISA (ED)</td>
<td>Low serum fetuin-A associates with increased mortality.</td>
</tr>
<tr>
<td>Wang et al. (2005)(^{13})</td>
<td>PD patients</td>
<td>ND</td>
<td>ELISA (ED)</td>
<td>Low fetuin-A associates with valvular calcification and mortality.</td>
</tr>
<tr>
<td>Honda et al. (2006)(^{39})</td>
<td>Patients with stage 5 CKD</td>
<td>ND</td>
<td>Nephelometry</td>
<td>Low serum fetuin-A predicts higher mortality.</td>
</tr>
<tr>
<td>Hermans et al. (2006)(^{18})</td>
<td>HD and PD patients</td>
<td>15,000 × g</td>
<td>Nephelometry</td>
<td>Low fetuin-A does not predict 60-minute aortic stiffness.</td>
</tr>
<tr>
<td>Jung et al. (2006)(^{17})</td>
<td>HD patients</td>
<td>520 × g</td>
<td>ELISA (BV)</td>
<td>Serum fetuin-A levels do not correlate with CACS.</td>
</tr>
<tr>
<td>Cozzolino et al. (2006)(^{40})</td>
<td>HD patients</td>
<td>ND</td>
<td>ELISA (ED)</td>
<td>Low fetuin-A correlates with increased cardiovascular calcification.</td>
</tr>
<tr>
<td>Mori et al. (2007)(^{14})</td>
<td>Healthy subjects</td>
<td>ND</td>
<td>ELISA (BV)</td>
<td>Serum fetuin-A levels associate with carotid artery stiffness.</td>
</tr>
<tr>
<td>Russo et al. (2007)(^{41})</td>
<td>Patients with stages 3 through 5 CKD</td>
<td>ND</td>
<td>ELISA (ED)</td>
<td>Serum fetuin-A is lower in patients with CAC.</td>
</tr>
<tr>
<td>Hermans et al. (2007)(^{42})</td>
<td>HD and PD patients</td>
<td>15,000 × g</td>
<td>Nephelometry</td>
<td>Low serum fetuin-A predicts 60-minute high mortality.</td>
</tr>
<tr>
<td>Ix et al. (2007)(^{43})</td>
<td>Patients with CAD</td>
<td>15,000 × g</td>
<td>Nephelometry</td>
<td>Low fetuin-A associates with 60-minute increased mitral annular calcification.</td>
</tr>
<tr>
<td>Ix et al. (2007)(^{19})</td>
<td>Patients with stages 3 and 4 CKD</td>
<td>ND</td>
<td>ELISA (ED)</td>
<td>Serum fetuin-A levels are not related to mortality.</td>
</tr>
<tr>
<td>Mikami et al. (2008)(^{15})</td>
<td>Patients with stages 1 through 5 CKD</td>
<td>ND</td>
<td>ELISA (ED)</td>
<td>Serum fetuin-A levels do not correlate with CACS.</td>
</tr>
<tr>
<td>Shroff et al. (2008)(^{44})</td>
<td>HD and PD patients</td>
<td>ND</td>
<td>ELISA (ED)</td>
<td>Aortic PWV negatively correlates with serum fetuin-A.</td>
</tr>
<tr>
<td>Metry et al. (2008)(^{45})</td>
<td>HD patients</td>
<td>ND</td>
<td>ELISA (ED)</td>
<td>Low serum fetuin-A associates with increased mortality only in the presence of inflammation.</td>
</tr>
<tr>
<td>Zheng et al. (2009)(^{46})</td>
<td>HD patients</td>
<td>ND</td>
<td>ELISA (ED)</td>
<td>Low serum fetuin-A correlates with increased CACS.</td>
</tr>
</tbody>
</table>

Published clinical studies on the relationship between fetuin-A and extraosseous calcification and/or mortality in adults are listed. Two analytical methods were used in these studies: ELISA and nephelometry. BV, BioVendor; CAC, coronary artery calcification; CAD, coronary artery disease; ED, Epitope Diagnostic; ND, not described; NRF, normal renal function; PD, peritoneal dialysis; PWV, pulse wave velocity. Bolded references are negative studies about fetuin-A.
with anti–fetuin-A antibody, and the turbidity derived from fetuin-A bound to the antibody is determined from light scattering. Because of this analytical principle, samples analyzed by nephelometry must be clarified by centrifugation at 15,000 \( \times g \). Although we separated human FMC at a slightly higher speed (16,000 \( \times g \)) following our animal experiments, the fetuin-A levels measured by nephelometry substantially correspond to supernatant fetuin-A in our study; therefore, ELISA and nephelometry measure different fractions of fetuin-A, and this should be considered when interpreting previous clinical findings. This could explain why most studies that used nephelometry yielded positive results whereas most of negative studies of serum fetuin-A used ELISAs (Table 1) and why serum fetuin-A levels are unreliable as a marker of extrasosseous calcification stress (Figures 5 and 6).

In conclusion, the ratio of FMC to total fetuin-A (i.e., RR) potentially reflects extrasosseous calcification stress, whereas supernatant fetuin-A is less reliable and serum fetuin-A is not a reliable indicator at all. Our results suggest that the measurement of FMC is required for assessment of ongoing extrasosseous calcification stress.

**CONCISE METHODS**

**Patient Recruitment**

We analyzed serum samples from 13 patients who were on HD to detect FMC directly (Figure 2). Eleven control subjects did not have diabetes or CKD and did not smoke (Figures 2 and 3). We also recruited 73 predialysis patients with CKD and diabetes from the outpatient services of Osaka University Hospital in Japan between April 2005 and April 2007 (Figures 3 through 5). Individuals who had progressed to ESRD that required dialysis or who had a history of myocardial infarction, coronary angioplasty, or coronary bypass surgery and those who were under or had received glucocorticoids for 3 months after the interventions in two patients who underwent PTX and provided informed consent. We adhered to the Declaration of Helsinki throughout this study. The ethics committee of Osaka University Hospital approved the study protocol, and all of the patients and control subjects provided written informed consent to participate in all aspects of the study.

**Data Collection**

Blood specimens were obtained from predialysis patients with diabetes on the day of consultation. Blood specimens were collected from HD patients before starting HD at 2 days after the last HD session. Clotted blood samples were separated by centrifugation for 15 minutes at room temperature at 3000 \( \times g \), and then the decanted serum was frozen at \(-80^\circ C\). iPTH was assayed using Elecsys PTH immunoradiometric assays kit (Roche Diagnostics, Meylan, France). Fetuin-A was measured using Human Fetuin-A ELISA kits (Epitope Diagnostics) according to the manufacturer’s instructions. Another Human Fetuin-A ELISA kit (BioVendor Laboratory Medicine, Brno, Czech Republic) was also used where indicated. A schema of the analytical procedure for fetuin-A is shown in Figure 1.

Serum samples (50 \( \mu l \)) were centrifuged for 2 hours at 4°C at 16,000 \( \times g \), and then fetuin-A levels in the supernatant fraction were measured using the Human Fetuin-A ELISA kits. For analysis of FMC (Figure 2), serum samples (1 ml) in 1.5-ml tubes were centrifuged for 2 hours at 4°C at 16,000 \( \times g \). The supernatant was discarded, and the tubes were rinsed twice with 1 ml of 150 mM NaCl and separated again by centrifugation for 5 minutes at 16,000 \( \times g \). Portions of pellets were dissolved in 15 \( \mu l \) of 150 mM HCl for calcium analysis (Figure 2C) using clinical diagnostic reagents (Wako, Osaka, Japan). Other portions of pellets were dissolved in 80 \( \mu l \) of Laemml buffer containing 60 mM EDTA, and 15-\( \mu l \) portions were resolved by 10 to 20% Super-Sep polyacrylamide gel (Wako, Osaka, Japan) electrophoresis and then stained with Cooamassie Brilliant Blue.

**Protein Identification by MALDI-TOF/MS**

Gel pieces containing proteins of interest were excised and subjected to in-gel digestion with sequencing-grade modified trypsin (Promega, Madison, WI). ZipTip C18–concentrated (Millipore, Schwalbach, Germany) tryptic digested samples were prepared by co-crystallization of a saturated solution of the matrix (\( \alpha \)-cyano-4-hydroxycinnamic acid in 50/50 vol/wt acetonitrile/0.1% trifluoroacetic acid in water). Mass spectra were recorded on a Bruker Ultraflex TOF/TOF (Bruker Daltonics, Bremen, Germany) in positive ion reflectron mode. Tryptic monoisotopic peptide masses were searched against National Center for Biotechnology Information and SwissProt databases using the Mascot (Matrix Science, London, UK) program.

**Multidetector Computed Tomography**

We evaluated CACS using multidetector computed tomography (16-slice technique; Light Speed Ultra 16; GE Yokokawa Medical Systems, Tokyo, Japan). Image acquisition was timed to coincide with the diastolic phase of the cardiac cycle at approximately 70% (total three phases) of the R wave-to-R wave interval as determined through electrocardiographic monitoring with a 2.5-mm gap between slices. Scanning time was approximately 30 seconds for the entire zone of interest.
that encompassed the whole heart. This equipment was capable of detecting lesions of a density of at least 130 Hounsfield units and a minimum area of 0.4882 mm². Total CACS was calculated using Smartscore software (GE Yokokawa Medical Systems) in modified Agatston units. Scanning proceeded at 120 kV and 300 mA. The mean radiation dose defined as volume computed tomography dose index was 11.85 mGy, the dose product length was 142.15 mGy, and the effective dose was 97.4%.

**Statistical Analyses**

Serum fetuin-A and supernatant fetuin-A were compared by the Wilcoxon signed ranks test. Differences in RR of fetuin-A among patients at various stages CKD and control patients were compared using Dunnet analysis with stage 5 CKD as a reference. Linear trends between CKD stages and RR were confirmed using the Jonckheere-Terpstra trend test. Linear regression analyses of two continuous parameters were performed using the least-squares method. All statistical tests were two-sided, and \( P < 0.05 \) was considered significant. All data were statistically analyzed using JMP 5.1.2J for Windows (SAS Institute, Cary, NC).

**ACKNOWLEDGMENTS**

This study was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (No. 18790564).

**DISCLOSURES**

None.

**REFERENCES**


Supplemental information for this article is available online at http://www.jasn.org/.

www.jasn.org CLINICAL RESEARCH

Fetuin-Mineral Complex in Humans 2007